Over the past 25 years, research in cancer therapeutics has largely focused on two distinct
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …

The relative insufficiency of insulin secretion and/or insulin action causes diabetes.
However, obesity and type 2 diabetes mellitus can be associated with an absolute increase …

Although treatment with immune checkpoint inhibitors provides promising benefit for patients
with cancer, optimal use is encumbered by high resistance rates and requires a thorough …

Failure of regulatory T (Treg) cells to properly control immune responses leads invariably to
autoimmunity and organ damage. Decreased numbers or impaired function of Treg cells …

Inhibitors against the p110δ isoform of phosphoinositide-3-OH kinase (PI (3) K) have shown
remarkable therapeutic efficacy in some human leukaemias,. As p110δ is primarily …

Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …

Purpose: We study CD38 levels in immunosuppressive CD4+ CD25highFoxp3+ regulatory
T cells (Treg) and further define immunomodulating effects of a therapeutic CD38 mAb …

Highlights•Preclinical studies support us of PI3K inhibitors in autoimmunity and
inflammation.•First in class PI3K inhibitor has been approved for treatment of B cell …

The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to
induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from …

CD38 (also known as T10) was identified in the late 1970s in the course of pioneering work
carried out at the Dana‐Farber Cancer Center (Boston, MA) that focused on the identification …